3.4.22.B50: papain-like proteinase 2
This is an abbreviated version!
For detailed information about papain-like proteinase 2, go to the full flat file.
Word Map on EC 3.4.22.B50
-
3.4.22.B50
-
polyproteins
-
replicase
-
coronaviruses
-
3clpro
-
isg15
-
3c-like
-
mhv-a59
-
nsp3
-
coronaviral
-
pp1ab
-
medicine
-
drug development
- 3.4.22.B50
- polyproteins
-
replicase
- coronaviruses
- 3clpro
- isg15
-
3c-like
-
mhv-a59
- nsp3
- coronaviral
- pp1ab
- medicine
- drug development
Reaction
responsible for the cleavages located at the N-terminus of the replicase polyprotein =
Synonyms
Erv-C, ervatamin-C, mouse hepatitis virus papain-like proteinase 2, papain-like accessory protease, papain-like cysteine proteinase, papain-like protease, papain-like protease domain 2, papain-like proteinase, PL2-PRO, PL2pro, PLP-2, PLP2, PLpro, SARS-coronavirus papain-like protease, SARS-CoV papain-like protease, SARS-CoV PLpro, severe acute respiratory syndrome coronavirus papain-like protease
ECTree
Advanced search results
Application
Application on EC 3.4.22.B50 - papain-like proteinase 2
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
drug development
-
the enzyme is an attractive antiviral drug target because it is essential for coronaviral replication. Targeting the enzyme with antiviral drugs may have an advantage in not only inhibiting viral replication but also inhibiting the dysregulation of signaling cascades in infected cells that may lead to cell death in surrounding, uninfected cells
medicine
medicine
-
PLpro is an important target for development of antiviral drugs that would inhibit viral replication and reduce mortality associated with outbreaks of SARS-CoV
medicine
-
viral strategy to modulate the host cell ubiquitination machinery to its advantage
medicine
-
the enzyme is a potential targets for antiviral drug development
medicine
vaccination of Shetland mares, either with deubiquitinase DUB-positive or DUB-negative recombinant equine arteritis virus. Upon challenge with the virulent KY84 strain of equine arteritis virus, both vaccine viruses proved to be replication competent in vivo. The DUB-negative virus provides a similar degree of protection against clinical disease as its DUB-positive parental counterpart. A possible improvement due to inactivation of PLP2 DUB activity could not be detected under these experimental conditions
medicine
-
vaccination of Shetland mares, either with deubiquitinase DUB-positive or DUB-negative recombinant equine arteritis virus. Upon challenge with the virulent KY84 strain of equine arteritis virus, both vaccine viruses proved to be replication competent in vivo. The DUB-negative virus provides a similar degree of protection against clinical disease as its DUB-positive parental counterpart. A possible improvement due to inactivation of PLP2 DUB activity could not be detected under these experimental conditions
-
medicine
-
viral strategy to modulate the host cell ubiquitination machinery to its advantage
-
medicine
-
PLpro is an important target for development of antiviral drugs that would inhibit viral replication and reduce mortality associated with outbreaks of SARS-CoV
-